Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Clin Pract Oncol. 2009 Jan;6(1):25-33. doi: 10.1038/ncponc1243. Epub 2008 Oct 21.

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.

Author information

1
Breast Oncology Clinical Trials Program, UCSF Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94115-1710, USA. michelle.melisko@ucsf.edu

Abstract

The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.

PMID:
18936791
DOI:
10.1038/ncponc1243
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center